BofA analyst Allen Lutz raised the firm’s price target on Hims & Hers to $25 from $23 and keeps a Buy rating on the shares. Overall, Q3 observed sales growth still points to about 5%-8% upside to Visible Alpha consensus revenue estimates, even after considering the deferral of 10%-20% of GLP-1 sales or $8M-$16M of deferred sales, the analyst tells investors, citing Bloomberg Second Measure credit and debit card data. While cautious on the duration of the compounded GLP-1 opportunity, the firm is “encouraged by strength in core,” the analyst added.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS: